July 12, 2016

Amicus Therapeutics Appoints Former FDA Division Deputy Director Andrew Mulberg as Vice President, Regulatory Strategy

July 6, 2016

Amicus Therapeutics Expands Biologics Pipeline with New Preclinical Program for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency

June 10, 2016

Amicus Therapeutics Appoints Craig A. Wheeler to Board of Directors